The application of network mapping in differential diagnosis of parkinsonian disorders

Abstract Although approximately 1–3% of the population over age 65 have Parkinson’s disease (PD), only about 75% of the patients diagnosed with parkinsonism have PD. The differential diagnosis of parkinsonian disorders based on clinical symptoms alone is particularly difficult during the early stages of the disease. A number of imaging strategies have been developed to differentiate between these clinically similar conditions. The assessment of abnormal patterns of brain metabolism, either by visual inspection or using computer-assisted algorithms, can be used to discriminate between classical PD and atypical variant conditions such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), or corticobasal ganglionic degeneration (CBGD). Recent advances in network quantification routines have created the basis for fully automated differential diagnosis. Using PET, investigators have identified specific disease-related spatial covariance patterns that are characteristic of PD and its variants. By computing pattern expression in individual patient scans, it has become possible to determine the likelihood of a specific diagnosis. In this review, we describe the various imaging techniques that have been used to diagnose PD with emphasis on the application of network tools. Analogous methods may have value in the assessment of other neurodegenerative and neuropsychiatric conditions.

[1]  D. Margouleff,et al.  Positron emission tomographic findings in Filipino X‐linked dystonia–parkinsonism , 1993, Annals of neurology.

[2]  Angelo Antonini,et al.  Tc‐99m ethylene cysteinate dimer SPECT in the differential diagnosis of parkinsonism , 2002, Movement disorders : official journal of the Movement Disorder Society.

[3]  Mircea Ariel Schoenfeld,et al.  Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging , 2004, NeuroImage.

[4]  W. Martin,et al.  The nigrostriatal dopaminergic pathway in Wilson's disease studied with positron emission tomography. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[5]  J R Moeller,et al.  The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[6]  David Eidelberg,et al.  The metabolic pathology of dopa‐responsive dystonia , 2005, Annals of neurology.

[7]  Willibald Gerschlager,et al.  Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study , 2002, Movement disorders : official journal of the Movement Disorder Society.

[8]  A. Rajput,et al.  Prevalence of movement disorders in elderly community residents. , 1994, Neuroepidemiology.

[9]  A. Parent,et al.  Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidium in basal ganglia circuitry , 1995, Brain Research Reviews.

[10]  V. Dhawan,et al.  SPECT imaging in Parkinson's disease. , 2001, Advances in neurology.

[11]  J R Moeller,et al.  The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies , 1990, Movement disorders : official journal of the Movement Disorder Society.

[12]  Alan C. Evans,et al.  Dopa decarboxylase activity of the living human brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  S. Gilman,et al.  11C-DTBZ and 18F-FDG PET measures in differentiating dementias. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  Anthony E. Lang,et al.  Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics , 2005 .

[15]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.

[16]  David Eidelberg,et al.  Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  D. Eidelberg,et al.  Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  James Ralph Moeller,et al.  Highly automated computer-aided diagnosis of neurological disorders using functional brain imaging , 2006, SPIE Medical Imaging.

[19]  V. Dhawan,et al.  Abnormal Metabolic Network Activity in Parkinson'S Disease: Test—Retest Reproducibility , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[21]  K. Leenders,et al.  Long‐term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride , 1997, Movement disorders : official journal of the Movement Disorder Society.

[22]  B. Giraudeau,et al.  Quantitative analysis of striatal dopamine D2 receptors with 123I-iodolisuride SPECT in degenerative extrapyramidal diseases , 2001, Nuclear medicine communications.

[23]  Nir Giladi,et al.  Metabolic topography of the hemiparkinsonism‐hemiatrophy syndrome , 1994, Neurology.

[24]  Anna Barnes,et al.  FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.

[25]  T. Ishikawa,et al.  Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Jan Booij,et al.  The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism , 2001, European Journal of Nuclear Medicine.

[27]  David Eidelberg,et al.  Regional metabolic changes in Parkinsonian patients with normal dopaminergic imaging , 2007, Movement disorders : official journal of the Movement Disorder Society.

[28]  T. Ishikawa,et al.  Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  V. Dhawan,et al.  10 – Movement Disorders: Parkinson's Disease , 2000 .

[30]  J R Moeller,et al.  Early differential diagnosis of Parkinson's disease with 18F‐fluorodeoxyglucose and positron emission tomography , 1995, Neurology.

[31]  M. Ghilardi,et al.  Effects of levodopa infusion on motor activation responses in Parkinson’s disease , 2002, Neurology.

[32]  V. Dhawan,et al.  Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease , 2001, Annals of neurology.

[33]  Robert B. Innis,et al.  [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy , 2001 .

[34]  N. Quinn,et al.  Multiple system atrophy: A review of 203 pathologically proven cases , 1997, Movement disorders : official journal of the Movement Disorder Society.

[35]  David Eidelberg,et al.  The role of functional neuroimaging in the differential diagnosis of idiopathic Parkinson’s disease and multiple system atrophy , 2004, Clinical Autonomic Research.

[36]  A. Parent,et al.  Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop , 1995, Brain Research Reviews.

[37]  Jean-Claude Baron,et al.  Executive processes in Parkinson's disease: FDG‐PET and network analysis , 2004, Human brain mapping.

[38]  Yaakov Stern,et al.  Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance , 2004, NeuroImage.

[39]  V. Dhawan,et al.  75 – PET Imaging in Parkinson's Disease and Other Neurodegenerative Disorders , 2007 .

[40]  J. C. Stoof,et al.  [123I]β-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls , 1997, European Journal of Nuclear Medicine.

[41]  T. Ishikawa,et al.  The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[43]  Klaus Seppi,et al.  Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. , 2005, Brain : a journal of neurology.

[44]  Daniel Tarsy,et al.  Adverse effects of subthalamic nucleus DBS in a patient with multiple system atrophy , 2003, Neurology.

[45]  V. Dhawan,et al.  Network modulation in the treatment of Parkinson's disease. , 2006, Brain : a journal of neurology.

[46]  A. Eisen,et al.  Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. , 1990, Archives of neurology.

[47]  Luc Mortelmans,et al.  Dual-tracer dopamine transporter and perfusion SPECT in differential diagnosis of parkinsonism using template-based discriminant analysis. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[48]  J. Seibyl,et al.  [123I]β-CIT SPECT imaging assessment of the rate of Parkinson’s disease progression , 2001, Neurology.

[49]  C Kremser,et al.  Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.

[50]  J R Moeller,et al.  Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing. , 1997, Brain : a journal of neurology.

[51]  M. Delong,et al.  Functional and pathophysiological models of the basal ganglia , 1996, Current Opinion in Neurobiology.

[52]  V. Dhawan,et al.  Dopamine transporter imaging with fluorine-18-FPCIT and PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[53]  V Kaasinen,et al.  Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  David Eidelberg,et al.  Modulation of regional brain function by deep brain stimulation: studies with positron emission tomography , 2002, Current opinion in neurology.

[55]  V. Dhawan,et al.  Radiosynthesis of [18F] N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane and the first human study with positron emission tomography , 1996 .

[56]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[57]  U. Haberkorn PET and SPECT. , 2008, Handbook of experimental pharmacology.

[58]  V. Dhawan,et al.  Reproducibility of regional metabolic covariance patterns: comparison of four populations. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[59]  C. Patlak,et al.  Combined FDOPA and 3OMFD PET studies in Parkinson's disease. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[60]  Masanori Ichise,et al.  Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP , 2002, Movement disorders : official journal of the Movement Disorder Society.

[61]  Koen Van Laere,et al.  Quantification of Parkinson’s disease-related network expression with ECD SPECT , 2007, European Journal of Nuclear Medicine and Molecular Imaging.